MaxCyte Appoints Ex-Genzyme Executive Richard Douglas Non-Executive

LONDON (Alliance News) - Biotechnology firm MaxCyte Inc said Tuesday that life sciences veteran ...

Alliance News 13 February, 2018 | 1:36PM
Email Form

LONDON (Alliance News) - Biotechnology firm MaxCyte Inc said Tuesday that life sciences veteran Richard Douglas had been appointed non-executive director with immediate effect.

Douglas previously served as senior vice president of corporate development at Genzyme Corp between 1989 and its acquisition by Sanofi SA in 2011.

"Richard's wealth of expertise in business and corporate development and his deep life sciences industry experience will bring invaluable perspective to the MaxCyte board," MaxCyte President & Chief Executive Officer Doug Doerfler said. "We are extremely pleased to have Richard as part of our organisation as we further our enablement of new medicines in the areas of gene editing and immuno-oncology, and move our first product candidate from our CARMA therapeutic platform into the clinic."

Douglas added: "I have followed MaxCyte's progress closely over the previous years and I believe its technology is truly revolutionary. With the first CARMA therapy due to enter the clinic later this year, I am delighted to join MaxCyte at this exciting time in its development. I look forward to working closely with the board and management team in bringing the next generation of treatments to patients."

Shares in MaxCyte were 0.5% lower at 248.66 pence on Tuesday.

By Ahren Lester; ahrenlester@alliancenews.com.

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar
Rating
MaxCyte Inc 236.00 GBX 0.00 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.